Azitra (AZTR) Net Equity Issued and Repurchased (2025 - 2026)

Azitra's (AZTR) quarterly Net Equity Issued and Repurchased came in at $215950.0 in Q1 2026, down 91.0% on a QoQ basis from $2.4 million in Q4 2025.

Azitra (AZTR) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends

Azitra (AZTR) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $215950.0 in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $215950.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, changed N/A from the prior year.
Net Equity Issued and Repurchased slipped to $215950.0 in Q1 2026, from $2.4 million in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $2.8 million in Q3 2025 to a low of $215950.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Azitra	2.53 Mn	2.53 Mn	-	-

Download Data